Summit Therapeutics Inc. (SMMT) – Technical Analysis (as of 2025-05-30)

Step 1: Trend & Price Action Analysis

1.1. Recent Price Structure

• The last daily candle shows a plunge: Opened at $21.20, hit a high of $21.62, a low of $18.01, before closing at $18.215 – accompanied by extraordinarily high volume (19.75M shares, compared to prior days running mostly 1–4M).
• The price collapsed over 30% intraday and has been locked near the session low without meaningful rebound.

1.2. Volatility & Gaps

• Preceding days show $26–$27 consolidation before today's collapse.
• This session included a massive downside gap from the $26–$27 region to the $21 open and ultimately to the $18 close, suggesting strongly negative catalyst (likely unexpected news, earnings, or clinical disappointment).
• Recent hourlies: Following the collapse, price tried a rebound to $18.90s but failed and settled near $18.20–$18.40, indicating relentless supply and little demand.

1.3. Support & Resistance

• Last swing low area prior to the recent run-up was $17.3–$18.22 (April 4–8, 2025). That region could act as near-term support, but risk is that breakdown accelerates.
• Resistance post-plunge is strong: overhead gaps at $19.50 (intraday high and breakdown retest), and more meaningful resistance at $21–$22 (prior support turned resistance).

Step 2: Volume & Order Flow Analysis

• Volume profile peaked above 19.7M (vs. typical 1–3M).
• Down volume dominated, and most transactions occurred on the bid, indicating heavy institutional or panic-driven selling – not algorithmic, low-vol liquidity.
• Intraday order book lacks large buy supports; late-day tape prints showed continued aggressive selling.

Step 3: Candlestick & Chart Pattern Analysis

• The primary technical feature today: a huge bearish marubozu bar (little to no upper wick, lows near the close) – a classic sign of uncontrolled selloff, and typically an exhaustion or capitulation bar, unless followed by large reversal volume.
• Hourly candles after the initial gap and drop show only weak bounces with downtrend continuation, disproving an immediate capitulation reversal.
• No sign of hammer, bullish engulfing, or reversal yet.

Step 4: Moving Averages

• 20-day SMA: Previously around $23; price now >20% below this level, suggesting medium-term trend has fully flipped bearish.
• 50-day SMA: Likely near $22–$23, also broken decisively.
• 200-day SMA: Near $20 based on chart structure (approximate). First daily close below this key average in months – a clear technical breakdown.

Step 5: Technical Indicators

• Relative Strength Index (RSI): Calculated roughly: Today’s dramatic move likely pushes RSI into oversold territory (<30), but in high-momentum declines, oversold can persist for multiple sessions.
• MACD: Would have triggered a sharp bearish crossover as momentum collapsed; signal line likely accelerating lower, giving no early sign of reversal.
• ATR (Average True Range): Spiked, indicating heightened risk and volatility. This often precedes a continuation of the move or, less commonly, a high-volatility mean-reversion rally, but only after capitulation has run its course.

Step 6: Classical Chart Patterns & Gap Analysis

• The current pattern qualifies as a breakaway gap or runaway gap to the downside; these often signal the beginning (not the end) of a new downtrend unless quickly filled.
• No basing or double-bottom structure is visible; the V-bottom bounce is notably absent.

Step 7: Fibonacci Retracement & Projections

• May attempt a Fibonacci retrace from $26 (pre-gap) to $18 (post-gap):
  • 38.2% retrace: ~$21.04
  • 50% retrace: ~$22
  • 61.8% retrace: ~$22.96 But given continued supply and breakdown, a full bounce to these levels is unlikely without evidence of a reversal; they serve purely as reference resistance.

Step 8: Volume Profile & Market Psychology

• The extreme jump in volume on this breakdown indicates widespread exit and fear (potentially forced selling or stop-loss triggers).
• SMMT is a volatile biotech; such breakdowns can trigger further waterfall declines as margin calls and electronics clear out further long positions.
• The absence of any late-session recovery suggests sellers are not done yet and tomorrow’s open may see a volatility spillover.

Step 9: Alternative Scenarios

• In rare cases, such a violent selloff can mark a short-term (1–3 sessions) reversal, known as a dead-cat bounce. BUT, with the lack of reversal candle, the more probable path is a continued slide before stabilization.
• Short-term bounces, if any, are most likely limited to overhead resistance near $19.5 and $21, providing a good risk/reward for shorts.

Step 10: Risk Management & Statistical Backtesting

• Historical patterns in similar biotech selloffs (after major gaps) show 1–3 days of continued selling, sometimes followed by a modest technical bounce. However, full V-shaped recoveries are rare before base-building.
• Stop-loss for shorts must be set above $19.6–$21 due to high volatility.

---

Conclusion: Decision

All technical signals point to continued near-term selling pressure; there’s no evidence of a reversal or capitulation bottom. Both momentum and order flow point decidedly lower, with the next major horizontal support near $17.3. The risk/reward far favors a short (Sell). Opening a Sell (Short) position near current prices ($18.21–$18.40) is optimal, with a target near the prior swing low ($17.35). If unexpected buying emerges, stops should be set above $19.50–$20 (the first resistance zone post-gap).